;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AL-8176: Phase II data

    Alios BioPharma Inc., South San Francisco, Calif. Product: AL-8176 Business: Infectious Molecular target: NA Description: Oral respiratory syncytial virus (RSV) nucleoside analog Indication: Treat respiratory syncytial …

    Published on 7/28/2014
  • Alpha-gal glycolipids: Phase I data

    Agalimmune Ltd., London, U.K. Product: Alpha-gal glycolipids Business: Cancer Molecular target: NA Description: Glycolipids expressing alpha-gal epitopes based on Alphaject technology Indication: Treat unresectable …

    Published on 7/28/2014
  • Aripiprazole lauroxil: Additional Phase III data

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: Aripiprazole lauroxil (ALKS 9072, ALKS 9070) Business: Neurology Molecular target: Dopamine D2 receptor; Serotonin (5-HT) receptor Description: Injectable, extended-…

    Published on 7/28/2014
  • BBI608: Phase Ib data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: BBI608 Business: Cancer Molecular target: NA Description: Small molecule targeting cancer stem cells Indication: Treat advanced malignancies …

    Published on 7/28/2014
  • BBI608: Phase I/II data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: BBI608 Business: Cancer Molecular target: NA Description: Small molecule targeting cancer stem cells Indication: Treat advanced solid tumors …

    Published on 7/28/2014
  • Brintellix vortioxetine: Phase II data

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Brintellix vortioxetine (formerly Lu AA21004) Business: Neurology Molecular target: Serotonin (5-HT3) …

    Published on 7/28/2014
  • Brivaracetam: Phase III data

    UCB Group (Euronext:UCB), Brussels, Belgium Product: Brivaracetam (formerly Rikelta) Business: Neurology Molecular target: Synaptic vesicle protein (SV2A) Description: High affinity synaptic vesicle protein (SV2A) …

    Published on 7/28/2014
  • Cerenis HDL: Phase II data

    Cerenis Therapeutics S.A., Labege, France Product: Cerenis HDL (CER-001) Business: Endocrine/Metabolic Molecular target: Apolipoprotein A-1 (APOA1) Description: Complex of recombinant apolipoprotein A-1 (APOA1) and …

    Published on 7/28/2014
  • Cerenis HDL: Phase II data

    Cerenis Therapeutics S.A., Labege, France Product: Cerenis HDL (CER-001) Business: Endocrine/Metabolic Molecular target: Apolipoprotein A-1 (APOA1) Description: Complex of recombinant apolipoprotein A-1 (APOA1) and …

    Published on 7/28/2014
  • Eltrombopag: Phase III data

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Eltrombopag (Promacta, Revolade) Business: Hematology Molecular target: Thrombopoietin (TPO) …

    Published on 7/28/2014
  • Gilotrif afatinib: Additional Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Gilotrif afatinib (Giotrif, Tomtovok) (BIBW 2992) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (HER1) (ErbB1); Epidermal growth …

    Published on 7/28/2014
  • Jakafi: Phase III data

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Jakafi ( Jakavi - EU) ruxolitinib (INCB18424) Business: Hematology Molecular target: Janus kinase-1 (JAK-1); …

    Published on 7/28/2014
  • Mitizax: Additional Phase III data

    ALK-Abello A/S (CSE:ALK-B), Horsholm, Denmark Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Mitizax (House Dust Mite Allergy Immunotherapy Tablet…

    Published on 7/28/2014
  • Mitizax: Additional Phase III data

    ALK-Abello A/S (CSE:ALK-B), Horsholm, Denmark Torii Pharmaceutical Co. Ltd. (Tokyo:4551), Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Mitizax (House Dust Mite Allergy Immunotherapy Tablet…

    Published on 7/28/2014
  • Nexavar sorafenib: Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Nexavar sorafenib Business: Cancer Molecular target: CRAF (RAF1); Vascular endothelial growth factor (VEGF) receptor …

    Published on 7/28/2014
  • NSI-189: Final Phase Ib data

    Neuralstem Inc. (NYSE-M:CUR), Rockville, Md. Product: NSI-189 Business: Neurology Molecular target: NA Description: Small molecule benzylpiperizine aminiopyridine that stimulates neurogenesis Indication: Treat major …

    Published on 7/28/2014
  • Olaptesed pegol: Additional Phase IIa data

    Noxxon Pharma AG, Berlin, Germany Product: Olaptesed pegol (NOX-A12) Business: Cancer Molecular target: Chemokine CXC motif ligand 12 (CXCL12) (SDF-1) Description: Chemokine CXC motif ligand 12 (CXCL12; SDF-1) inhibitor…

    Published on 7/28/2014
  • Olaptesed pegol: Additional Phase IIa data

    Noxxon Pharma AG, Berlin, Germany Product: Olaptesed pegol (NOX-A12) Business: Cancer Molecular target: Chemokine CXC motif ligand 12 (CXCL12) (SDF-1) Description: Chemokine CXC motif ligand 12 (CXCL12; SDF-1) inhibitor…

    Published on 7/28/2014
  • Oral neratinib: Phase III data

    Puma Biotechnology Inc. (NYSE:PBYI), Los Angeles, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Oral neratinib (HKI-272, PB272) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (…

    Published on 7/28/2014
  • Orencia abatacept: Phase IIIb data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Orencia abatacept (ONO-4164IV) Business: Autoimmune Molecular target: CD80 (B7-1); CD86 (B7-2) …

    Published on 7/28/2014
  • PA-824: Phase IIb data

    Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), Shanghai, China Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Global Alliance for TB Drug Development, New York, N.Y. Product: PA-824 …

    Published on 7/28/2014
  • SAGE-547: Preliminary Phase I/II data

    Sage Therapeutics Inc. (NASDAQ:SAGE), Cambridge, Mass. Product: SAGE-547 Business: Neurology Molecular target: GABA A receptor Description: Positive allosteric modulator (PAM) of GABA A receptor Indication: Treat super-…

    Published on 7/28/2014
  • Vacc-4x: Phase I/II data

    Bionor Pharma ASA (OSE:BIONOR), Oslo, Norway Product: Vacc-4x Business: Infectious Molecular target: NA Description: Peptide-based therapeutic vaccine composed of 4 modified HIV Gag p24 consensus peptides Indication: …

    Published on 7/28/2014
  • Varlilumab: Additional Phase I data

    Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: Varlilumab (CDX-1127) Business: Cancer Molecular target: CD27 Description: Human mAb targeting CD27 Indication: Treat hematologic cancers and solid tumors…

    Published on 7/28/2014
  • VGX-3100: Phase II data

    Inovio Pharmaceuticals Inc. (NYSE-M:INO), Blue Bell, Pa. Product: VGX-3100 Business: Infectious Molecular target: Human papillomavirus (HPV) antigens Description: DNA-based therapeutic vaccine targeting the E6 and E7 …

    Published on 7/28/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993